GeneDx Holdings Corp. Class A (WGS)

GeneDx Holdings Corp. (WGS) stock has experienced significant fluctuations in the past six months. The stock surged over 2,500% since early 2024, reaching an all-time high of $117.50 on April 28, 2025, and a 52-week high of $170.75 by November 27, 2025. However, shares plunged by nearly half after the Q1 2025 financial report, despite the company beating top and bottom-line estimates and raising its full-year guidance, due to a sequential dip in exome/genome panel volumes, which was influenced by seasonality. In Q3 2025, GeneDx reported revenue of $116.7 million, beating expectations by 52% year-over-year, but missed EPS forecasts, leading to a 2.04% dip in pre-market trading. Subsequent surges in the stock price have been fueled by positive sentiment, including major analyst upgrades from firms like Guggenheim and BTIG, which raised price targets and maintained "Buy" ratings, citing robust growth in exome and genome testing. More recently, in November 2025, a director's sale of 38,000 shares prompted some profit-taking.

Demand for GeneDx Holdings Corp.'s products and services exhibits seasonality. The company typically experiences higher testing volume in the fourth quarter (Q4) and lower volume in the first quarter (Q1). This seasonal pattern is primarily due to patients meeting their annual insurance deductibles, leading to increased healthcare spending towards the end of the year.

GeneDx Holdings Corp. (WGS) is a genomics company specializing in genetic testing services, primarily focusing on pediatric and rare disease diagnostics. The company operates within the Healthcare sector, specifically in the Diagnostics & Research and Medical/Nursing Services industries. GeneDx's major products include whole exome and genome sequencing, as well as data and information services. They also develop an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

GeneDx Holdings Corp. is headquartered in Stamford, Connecticut, United States. The company's stock is also traded on the Berne Stock Exchange in Switzerland.

In the past year, GeneDx Holdings Corp. has demonstrated robust revenue growth and is recognized for its market leadership in genomics. The company has received a consensus "Moderate Buy" recommendation from analysts and scored higher than 57% of companies evaluated by MarketBeat in the medical sector. However, the company's reputation has faced challenges, including allegations from former employees that the company's previous healthcare data platform, Centrellis, was misrepresented to gain a higher stock market multiple. Furthermore, GeneDx, under its former name Sema4, had a dispute with UnitedHealthcare in 2022, resulting in a $42 million settlement, with allegations of "code stacking," an illegal practice to inflate revenue, continuing to impact the company.

The ownership structure of GeneDx Holdings (WGS) stock is a mix of institutional, insider, and individual investors. Approximately 61.72% of the company's stock is held by institutional investors, while insiders hold 29.60%. Major institutional owners include Corvex Management LP, Casdin Capital, LLC, BlackRock, Inc., William Blair Investment Management, Llc, Vanguard Group Inc, Goldman Sachs Group Inc, and Oracle Investment Management Inc. Eli Casdin is noted as the largest individual shareholder. In the past three months, insiders have sold more company stock than they have bought.